The Correlation of Rapid Antibody Results with SARS-CoV-2 PCR in COVID-19 Patients in Ulin General Hospital Banjarmasin
Downloads
Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of clinical disease, better known as COVID-19. The most common method to detect COVID-19 is serological testing of IgM and IgG in response to viral infections using rapid diagnostic test (RDT). Several other guidelines consider polymerase chain reaction (PCR) as the gold standard for diagnosis becausePCR has high sensitivity and specificity values in detecting SARS-CoV-2.
Methods: This was a descriptive analytical study. The samples were taken from medical records of COVID-19 patients in Ulin General Hospital Banjarmasin from March to October 2020. Statistical Package for the Social Sciences (SPSS) 16.0 software and Chi-Square test were used for data analysis.
Results: From 751 COVID-19 patients, 408 patients (54.32%) had rapid antibody with positive PCR, 132 patients (17.57%) had reactive rapid antibody with negative PCR, 152 patients (20.23%) had non-reactive rapid antibody with positive PCR, and 59 patients (7.85%) had non-reactive rapid antibody with negative PCR. The rapid antibody had sensitivity of 72.85% and specificity of 30.89%. From Chi-Square test, reactive rapid antibody was not correlated with PCR positive results; values of p = 0.320, odds ratio (OR) 1.20.
Conclusion: The rapid test antibody could not be recommended as a diagnostic tool. In this study, it was also found that there was no relationship between reactive rapid test results and positive SARS-CoV PCR.
Böger B, Fachi MM, Vilhena RO, et al. Systematic Review with Meta-Analysis of the Accuracy of Diagnostic Tests for COVID-19. Am J Infect Control 2021; 49: 21–29.
Nicol T, Lefeuvre C, Serri O, et al. Assessment of SARS-CoV-2 Serological Tests for the Diagnosis of COVID-19 through the Evaluation of Three Immunoassays: Two Automated Immunoassays (Euroimmun and Abbott) and One Rapid Lateral Flow Immunoassay (NG Biotech). J Clin Virol 2020; 129: 104511.
Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323: 1574–1581.
Tan L, Kang X, Ji X, et al. Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study. Med (New York, NY) 2020; 1: 128-138.e3.
Gamboa E, Duran M, Araiza A, et al. The Use of COVID-19 IgM Rapid Test in the Setting of Negative RT-PCR to Diagnose Infection by SARS-CoV-2: A Challenging Case. Crit Care Shock 2020; 23: 148–153.
Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019. Clin Infect Dis 2020; 71: 2027–2034.
Organization WH. Saran Penggunaan Tes Imunodiagnostik di Fasyankes (Point of Care) untuk COVID-19. Geneva, https://www.who.int/docs/default-source/searo/indonesia/covid19/saran-penggunaan-tes-imunodiagnostik-di-fasyankes-(point-of-care)-untuk-covid-19.pdf?sfvrsn=a428857b_2 (2020).
Traugott MT, Hoepler W, Seitz T, et al. Diagnosis of COVID-19 Using Multiple Antibody Assays in Two Cases with Negative PCR Results from Nasopharyngeal Swabs. Infection 2021; 49: 171–175.
Ong DSY, de Man SJ, Lindeboom FA, et al. Comparison of Diagnostic Accuracies of Rapid Serological Tests and ELISA to Molecular Diagnostics in Patients with Suspected Coronavirus Disease 2019 Presenting to the Hospital. Clin Microbiol Infect 2020; 26: 1094.e7-1094.e10.
Van Elslande J, Houben E, Depypere M, et al. Diagnostic Performance of Seven Rapid IgG/IgM Antibody Tests and the Euroimmun IgA/IgG ELISA in COVID-19 Patients. Clin Microbiol Infect 2020; 26: 1082–1087.
Capello F, Cipolla M, Cosco L, et al. The VivaDiag COVID-19 lgM/IgG Rapid Test for the Screening and Early Diagnosis of COVID-19 in Patients with No Clinical Signs of the Disease. Int J Endocrinol Metab; 6. Epub ahead of print 11 May 2020. DOI: 10.16966/2380-548X.167.
Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020; 324: 782–793.
Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review. Ann Intern Med 2020; 172: 726–734.
Bai H, Xiaolong C, Zhang X. Landscape Coronavirus Disease 2019 test (COVID-19 test) in Vitro -- A Comparison of PCR vs Immunoassay vs Crispr-Based Test. 2020. Epub ahead of print 21 March 2020. DOI: 10.31219/osf.io/6eagn.
Li Z, Yi Y, Luo X, et al. Development and Clinical Application of a Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. J Med Virol 2020; 92: 1518–1524.
Triyani Y, Noormartany, Nilapsari R. COVID-19 dan Peran Pemeriksaan Laboratorium. In: Respati T, Rathomi HS (eds) Kopidpedia: Bunga Rampai Artikel Penyakit Virus Korona (COVID-19). Bandung: Pusat Penerbitan Universitas (P2U) Universitas Islam Bandung, pp. 45–61.
Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 2020; 71: 778–785.
Prasitsirikul W, Pongpirul K, Pongpirul WA, et al. Nurse Infected with COVID-19 from a Provisional Dengue Patient. Emerging Microbes & Infections 2020; 9: 1354–1355.
Kembuan GJ. Dengue Serology in Indonesian COVID-19 Patients: Coinfection or Serological Overlap? IDCases 2020; 22: e00927.
Spinicci M, Bartoloni A, Mantella A, et al. Low Risk of Serological Cross-Reactivity between Dengue and COVID-19. Mem Inst Oswaldo Cruz 2020; 115: e200225.
Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody Tests for Identification of Current and Past Infection with SARS-CoV-2. Cochrane Database Syst Rev 2020; 6: CD013652.
Yuen K-S, Ye Z-W, Fung S-Y, et al. SARS-CoV-2 and COVID-19: The Most Important Research Questions. Cell Biosci 2020; 10: 40.
Döhla M, Boesecke C, Schulte B, et al. Rapid Point-of-Care Testing for SARS-CoV-2 in a Community Screening Setting Shows Low Sensitivity. Public Health 2020; 182: 170–172.
Organization WH. Tes Diagnostik untuk SARS-CoV-2. Geneva, https://www.who.int/docs/default-source/searo/indonesia/covid19/tes-diagnostik-untuk-sars-cov-2.pdf?sfvrsn=71ceeae7_2 (2020).
Yanti B, Ismida F, Sarah K. Perbedaan Uji Diagnostik Antigen, Antibodi, RT-PCR dan Tes Cepat Molekuler pada Coronavirus Disease 2019. J Kedokt Syiah Kuala; 20. Epub ahead of print 1 December 2020. DOI: 10.24815/jks.v20i3.18719.
Wahjudi M. Kontroversi Metode Deteksi COVID-19 di Indonesia. KELUWIH J Kesehat dan Kedokt 2020; 2: 32.
Acer Ö, Özüdoğru O. Comparison of Real-Time Reverse Transcriptase-Polymerase Chain Reaction (RT- PCR) and IgM and IgG Antibody Test for the Diagnosis of SARS-CoV-2 Infection. 2020; 78–86.
Liu R, Liu X, Han H, et al. The Comparative Superiority of IgM-IgG Antibody Test to Real-Time Reverse Transcriptase PCR Detection for SARS-CoV-2 Infection Diagnosis. medRxiv 2020; 2020.03.28.20045765.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (